Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Dolutegravir and Its Combination Drug Market Size Growth Rate by Type (2014-2025)
1.4.2 Dolutegravir
1.4.3 Abacavir/Dolutegravir/Lamivudine
1.4.4 Dolutegravir/Rilpivirine
1.5 Market by Application
1.5.1 Global Dolutegravir and Its Combination Drug Market Share by Application (2019-2025)
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Drug Center
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Dolutegravir and Its Combination Drug Market Size
2.2 Dolutegravir and Its Combination Drug Growth Trends by Regions
2.2.1 Dolutegravir and Its Combination Drug Market Size by Regions (2019-2025)
2.2.2 Dolutegravir and Its Combination Drug Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
3.1 Dolutegravir and Its Combination Drug Market Size by by Players
3.1.1 Global Dolutegravir and Its Combination Drug Revenue by by Players (2014-2019)
3.1.2 Global Dolutegravir and Its Combination Drug Revenue Market Share by by Players (2014-2019)
3.1.3 Global Dolutegravir and Its Combination Drug Market Concentration Ratio (CR5 and HHI)
3.2 Dolutegravir and Its Combination Drug Key Players Head office and Area Served
3.3 Key Players Dolutegravir and Its Combination Drug Product/Solution/Service
3.4 Date of Enter into Dolutegravir and Its Combination Drug Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Dolutegravir and Its Combination Drug Market Size by Type (2014-2019)
4.2 Global Dolutegravir and Its Combination Drug Market Size by Application (2014-2019)
5 North America
5.1 North America Dolutegravir and Its Combination Drug Market Size (2014-2019)
5.2 Dolutegravir and Its Combination Drug Key Players in North America
5.3 North America Dolutegravir and Its Combination Drug Market Size by Type
5.4 North America Dolutegravir and Its Combination Drug Market Size by Application
6 Europe
6.1 Europe Dolutegravir and Its Combination Drug Market Size (2014-2019)
6.2 Dolutegravir and Its Combination Drug Key Players in Europe
6.3 Europe Dolutegravir and Its Combination Drug Market Size by Type
6.4 Europe Dolutegravir and Its Combination Drug Market Size by Application
7 China
7.1 China Dolutegravir and Its Combination Drug Market Size (2014-2019)
7.2 Dolutegravir and Its Combination Drug Key Players in China
7.3 China Dolutegravir and Its Combination Drug Market Size by Type
7.4 China Dolutegravir and Its Combination Drug Market Size by Application
8 Japan
8.1 Japan Dolutegravir and Its Combination Drug Market Size (2014-2019)
8.2 Dolutegravir and Its Combination Drug Key Players in Japan
8.3 Japan Dolutegravir and Its Combination Drug Market Size by Type
8.4 Japan Dolutegravir and Its Combination Drug Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Dolutegravir and Its Combination Drug Market Size (2014-2019)
9.2 Dolutegravir and Its Combination Drug Key Players in Southeast Asia
9.3 Southeast Asia Dolutegravir and Its Combination Drug Market Size by Type
9.4 Southeast Asia Dolutegravir and Its Combination Drug Market Size by Application
10 India
10.1 India Dolutegravir and Its Combination Drug Market Size (2014-2019)
10.2 Dolutegravir and Its Combination Drug Key Players in India
10.3 India Dolutegravir and Its Combination Drug Market Size by Type
10.4 India Dolutegravir and Its Combination Drug Market Size by Application
11 Central & South America
11.1 Central & South America Dolutegravir and Its Combination Drug Market Size (2014-2019)
11.2 Dolutegravir and Its Combination Drug Key Players in Central & South America
11.3 Central & South America Dolutegravir and Its Combination Drug Market Size by Type
11.4 Central & South America Dolutegravir and Its Combination Drug Market Size by Application
12 International Players Profiles
12.1 ViiV Healthcare (GSK)
12.1.1 ViiV Healthcare (GSK) Company Details
12.1.2 Company Description and Business Overview
12.1.3 Dolutegravir and Its Combination Drug Introduction
12.1.4 ViiV Healthcare (GSK) Revenue in Dolutegravir and Its Combination Drug Business (2014-2019))
12.1.5 ViiV Healthcare (GSK) Recent Development
12.2 Adcock Ingram Limited
12.2.1 Adcock Ingram Limited Company Details
12.2.2 Company Description and Business Overview
12.2.3 Dolutegravir and Its Combination Drug Introduction
12.2.4 Adcock Ingram Limited Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.2.5 Adcock Ingram Limited Recent Development
12.3 Aurobindo Pharma
12.3.1 Aurobindo Pharma Company Details
12.3.2 Company Description and Business Overview
12.3.3 Dolutegravir and Its Combination Drug Introduction
12.3.4 Aurobindo Pharma Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.3.5 Aurobindo Pharma Recent Development
12.4 Cipla
12.4.1 Cipla Company Details
12.4.2 Company Description and Business Overview
12.4.3 Dolutegravir and Its Combination Drug Introduction
12.4.4 Cipla Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.4.5 Cipla Recent Development
12.5 Emcure Pharmaceuticals
12.5.1 Emcure Pharmaceuticals Company Details
12.5.2 Company Description and Business Overview
12.5.3 Dolutegravir and Its Combination Drug Introduction
12.5.4 Emcure Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.5.5 Emcure Pharmaceuticals Recent Development
12.6 LAURUS Labs
12.6.1 LAURUS Labs Company Details
12.6.2 Company Description and Business Overview
12.6.3 Dolutegravir and Its Combination Drug Introduction
12.6.4 LAURUS Labs Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.6.5 LAURUS Labs Recent Development
12.7 Mylan
12.7.1 Mylan Company Details
12.7.2 Company Description and Business Overview
12.7.3 Dolutegravir and Its Combination Drug Introduction
12.7.4 Mylan Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.7.5 Mylan Recent Development
12.8 Ranbaxy Pharmaceuticals
12.8.1 Ranbaxy Pharmaceuticals Company Details
12.8.2 Company Description and Business Overview
12.8.3 Dolutegravir and Its Combination Drug Introduction
12.8.4 Ranbaxy Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.8.5 Ranbaxy Pharmaceuticals Recent Development
12.9 Shanghai Desano Pharmaceuticals
12.9.1 Shanghai Desano Pharmaceuticals Company Details
12.9.2 Company Description and Business Overview
12.9.3 Dolutegravir and Its Combination Drug Introduction
12.9.4 Shanghai Desano Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.9.5 Shanghai Desano Pharmaceuticals Recent Development
12.10 JNJ
12.10.1 JNJ Company Details
12.10.2 Company Description and Business Overview
12.10.3 Dolutegravir and Its Combination Drug Introduction
12.10.4 JNJ Revenue in Dolutegravir and Its Combination Drug Business (2014-2019)
12.10.5 JNJ Recent Development
13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
【掲載企業】
ViiV Healthcare (GSK)、Adcock Ingram Limited、Aurobindo Pharma、Cipla、Emcure Pharmaceuticals、LAURUS Labs、Mylan、Ranbaxy Pharmaceuticals、Shanghai Desano Pharmaceuticals、JNJ